{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:36:41Z","timestamp":1780072601084,"version":"3.54.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French National Reference Center for Antimicrobial Resistance"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cefepime\/enmetazobactam is a newly approved \u03b2-lactam\/\u03b2-lactamase inhibitor combination with promising activity against MDR Gram-negative Enterobacterales, particularly ESBL- and OXA-48-producing isolates. Reliable susceptibility testing methods are essential to guide its clinical use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the performance of two commercial cefepime\/enmetazobactam susceptibility testing methods, disc diffusion and Liofilchem\u2122 MTS gradient strips, using broth microdilution (BMD) as the gold standard.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 291 carbapenem-resistant Enterobacterales isolates, including 194 carbapenemase producers, were included. Susceptibility testing was performed using BMD, disc diffusion and Liofilchem\u2122 MTS strips. Results were interpreted following EUCAST and FDA 2025 breakpoints. Essential agreement (EA) and bias were calculated for gradient strip methods according to the ISO 20776-2021 guideline, whereas categorical agreement (CA), very major errors (VMEs) and major errors (MEs) were determined for disc diffusion according to the ISO 20776-2:2007 guideline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The disc diffusion method demonstrated high CA (93.8% EUCAST, 95.9% FDA). VME rates exceeded acceptable thresholds using EUCAST breakpoints (20.8%) but were within limits for FDA (1.9%). Liofilchem\u2122 MTS strips achieved 88.3% (95% CI: 84.1%\u201391.5%) EA and a bias of \u22128.9%. Both methods accurately detected susceptibility in OXA-48-producing isolates but showed limitations for isolates close to the MIC breakpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Disc diffusion and Liofilchem\u2122 MTS strips represent reliable alternatives to BMD for routine cefepime\/enmetazobactam testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf051","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:20:47Z","timestamp":1740471647000},"page":"1220-1223","source":"Crossref","is-referenced-by-count":3,"title":["Comparative evaluation of disc diffusion and Liofilchem\u2122 MTS strip methods with broth microdilution for cefepime\/enmetazobactam susceptibility testing"],"prefix":"10.1093","volume":"80","author":[{"given":"C\u00e9cile","family":"Emeraud","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases \u00bb (IMVA-HB\/IDMIT\/UMRS1184), Team Resist , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Bacteriology-Hygiene Unit, Bic\u00eatre Hospital Assistance Publique-H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hippolyte","family":"De Swardt","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases \u00bb (IMVA-HB\/IDMIT\/UMRS1184), Team Resist , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Bacteriology-Hygiene Unit, Bic\u00eatre Hospital Assistance Publique-H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Bernabeu","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases \u00bb (IMVA-HB\/IDMIT\/UMRS1184), Team Resist , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Bacteriology-Hygiene Unit, Bic\u00eatre Hospital Assistance Publique-H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Latour","sequence":"additional","affiliation":[{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Pages","sequence":"additional","affiliation":[{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ronsin","sequence":"additional","affiliation":[{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my A","family":"Bonnin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases \u00bb (IMVA-HB\/IDMIT\/UMRS1184), Team Resist , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Bacteriology-Hygiene Unit, Bic\u00eatre Hospital Assistance Publique-H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-7384","authenticated-orcid":false,"given":"Laurent","family":"Dortet","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases \u00bb (IMVA-HB\/IDMIT\/UMRS1184), Team Resist , Fontenay-aux-Roses & Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Bacteriology-Hygiene Unit, Bic\u00eatre Hospital Assistance Publique-H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"2025050205522363700_dkaf051-B1","doi-asserted-by":"publisher","first-page":"105925","DOI":"10.1016\/j.ijantimicag.2020.105925","article-title":"In vitro efficacy of imipenem-relebactam and cefepime\/AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae","volume":"56","author":"Tselepis","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025050205522363700_dkaf051-B2","doi-asserted-by":"publisher","first-page":"e0167621","DOI":"10.1128\/AAC.01676-21","article-title":"Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales","volume":"66","author":"V\u00e1zquez-Ucha","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205522363700_dkaf051-B3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025050205522363700_dkaf051-B4","doi-asserted-by":"publisher","first-page":"e00105\u201319","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam\u2212\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205522363700_dkaf051-B5","doi-asserted-by":"publisher","first-page":"e00514-19","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime\/enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025050205522363700_dkaf051-B6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jama.2022.22873","article-title":"Cefepime\/enmetazobactam vs piperacillin\/tazobactam and complicated urinary tract infection or acute pyelonephritis-reply","volume":"329","author":"Kaye","year":"2023","journal-title":"JAMA"},{"key":"2025050205522363700_dkaf051-B7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime\/enmetazobactam on carbapenem resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2025050205522363700_dkaf051-B8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/QCO.0000000000000984","article-title":"Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives","volume":"36","author":"Bassetti","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"2025050205522363700_dkaf051-B9","author":"Center for Drug Evaluation and Research"},{"key":"2025050205522363700_dkaf051-B10","doi-asserted-by":"publisher","first-page":"2300095","DOI":"10.2807\/1560-7917.ES.2023.28.42.2300095","article-title":"Emergence and rapid dissemination of highly resistant NDM-14-producing Klebsiella pneumoniae ST147, France, 2022","volume":"28","author":"Emeraud","year":"2023","journal-title":"Euro Surveill"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1220\/62163297\/dkaf051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/5\/1220\/62163297\/dkaf051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:52:27Z","timestamp":1746179547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/5\/1220\/8041833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf051","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,25]]}}}